Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- JCR Pharmaceuticals Announces Favorable Results from PI/II Trial of Stem-cell-based Therapy
February 27, 2012
- Diabetes Treatments: Their Development and Market (2)
February 27, 2012
- Daiichi Sankyo and Terumo Codevelop Intradermal Vaccine
February 24, 2012
- Nichi-Iko and Pfizer Japan Obtain Approval for Cisplatin Generic for Indication of Biliary Tract Cancer
February 24, 2012
- Ajinomoto Pharm. Files NDA for New Oral Bowel Cleansing Agent in Japan
February 24, 2012
- SymBio’s Licensee InnoPharmax Launches Bendamustine in Taiwan
February 24, 2012
- Eli Lilly Receives Approval for Zyprexa, First for Depression in Bipolar Disorder
February 23, 2012
- Use of Rasilez in Combination with ACE Inhibitors, ARBs in Patients with Diabetes to Be Contraindicated in Europe: Novartis
February 23, 2012
- RaQualia Maintains Focus on Pain, GI Diseases in New Midterm Management Plan
February 23, 2012
- Novo Nordisk President Says “Current Pipeline Most Substantial”
February 22, 2012
- Takeda’s Ulcerative Colitis Treatment Vedolizumab Shows Significant Improvement and Remission in Global PIII Trial
February 22, 2012
- CMIC HD Files NDA for UCD Treatment in Japan
February 22, 2012
- Shionogi, Eli Lilly Japan Announce Add’l Indication of DNP for Cymbalta
February 22, 2012
- IBL: ADAMTS5 Test Kit for Predicting Efficacy of Biologic Treatments in RA
February 22, 2012
- Glivec Receives Add’l Indication for HES/CEL: Novartis Pharma
February 22, 2012
- Cellectis of France Surrenders Claim for Damages Against Shionogi
February 22, 2012
- DSP Obtains Approval for Myslee Generic, Boosting Efforts to Strengthen CNS Field
February 21, 2012
- Pfizer Japan, DSP Apply for Pediatric Indication for Norvasc and Amlodin Based on Data from Public Domain
February 21, 2012
- Astellas, SKK Announce Alliance in Field of Kidney Diseases
February 21, 2012
- Nichi-Iko Makes Yakuhan Subsidiary to Expand Disinfectant Lineup
February 21, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…